AP2334A - Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. - Google Patents

Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.

Info

Publication number
AP2334A
AP2334A AP2007004031A AP2007004031A AP2334A AP 2334 A AP2334 A AP 2334A AP 2007004031 A AP2007004031 A AP 2007004031A AP 2007004031 A AP2007004031 A AP 2007004031A AP 2334 A AP2334 A AP 2334A
Authority
AP
ARIPO
Prior art keywords
inflamatory
treatment
heterocyclic compounds
compounds useful
allergic disorders
Prior art date
Application number
AP2007004031A
Other languages
English (en)
Other versions
AP2007004031A0 (en
Inventor
Laxmikant Atmaram Gharat
Balasubramanian Gopalan
Neelima Khairatkar-Joshi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AP2007004031A0 publication Critical patent/AP2007004031A0/xx
Application granted granted Critical
Publication of AP2334A publication Critical patent/AP2334A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2007004031A 2004-12-17 2005-12-15 Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. AP2334A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63723204P 2004-12-17 2004-12-17
IN1352MU2004 2004-12-17
PCT/IB2005/003798 WO2006064355A2 (fr) 2004-12-17 2005-12-15 Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques

Publications (2)

Publication Number Publication Date
AP2007004031A0 AP2007004031A0 (en) 2007-06-30
AP2334A true AP2334A (en) 2011-12-06

Family

ID=36384379

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004031A AP2334A (en) 2004-12-17 2005-12-15 Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.

Country Status (18)

Country Link
US (1) US8129401B2 (fr)
EP (1) EP1831227B1 (fr)
JP (1) JP5122974B2 (fr)
KR (1) KR101317119B1 (fr)
AP (1) AP2334A (fr)
AR (1) AR066386A1 (fr)
AU (1) AU2005315319B2 (fr)
BR (1) BRPI0517211B8 (fr)
CA (1) CA2591438C (fr)
EA (1) EA014956B1 (fr)
IL (1) IL183827A (fr)
MA (1) MA29231B1 (fr)
MX (1) MX2007007345A (fr)
MY (1) MY143483A (fr)
NZ (1) NZ555809A (fr)
PL (1) PL1831227T3 (fr)
TW (1) TWI359814B (fr)
WO (1) WO2006064355A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573348A (zh) * 2006-09-11 2009-11-04 矩阵实验室有限公司 作为pde-4和pde-10的抑制剂的二苯并呋喃衍生物
RU2334514C1 (ru) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2008081282A2 (fr) * 2006-12-20 2008-07-10 Glenmark Pharmaceuticals S.A. Procédé pour la synthèse de n9-(3,5-dichloro-4-pyridyl)-6- difluorométhoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide et leurs sels
WO2008093221A2 (fr) * 2007-02-01 2008-08-07 Glenmark Pharmaceuticals, S.A. Compositions pharmaceutiques pour le traitement de troubles inflammatoires et allergiques
WO2008142542A2 (fr) * 2007-05-22 2008-11-27 Glenmark Pharmaceuticals, S.A. Nouveaux procédés de préparation de 6-(difluorométhoxy) [1]benzofuro [3,2-c]pyridine-9-carbaldéhyde, nouvel intermédiaire pour la synthèse d'inhibiteurs de phosphodiestérases de type iv
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
EP2231600B1 (fr) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Composés de carboxamide, de sulfonamide et d'amine pour des troubles métaboliques
EP2231666B1 (fr) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Composés de carboxamide, de sulfonamide et d'amine servant a traiter les troubles métaboliques
EP2070913A1 (fr) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase
CA2727055C (fr) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. Pyridoindoles (1-azinone)-substitues en tant qu'antagonistes mch
WO2009132136A1 (fr) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Composés de carboxamide pour le traitement de troubles métaboliques
BRPI1014821A2 (pt) 2009-04-09 2016-04-05 Boehringer Ingelheim Int "inibidores de replicação de hiv"
WO2011019417A1 (fr) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido[4,3-b]indoles et leurs méthodes d'utilisation
WO2010127177A1 (fr) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido[4,3-b]indoles et procédés d'utilisation
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azabicycloalcane-indoles et azabicycloalcane-pyrrolo-pyridines substitués par azinone, leurs procédés de fabrication et leur utilisation
WO2011003012A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azapolycycles substitués par azinone, leurs procédés de fabrication et leur utilisation
WO2011003005A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azépino[b]indole et pyrido-pyrrolo-azépine azinone-substitué, procédés de préparation, et utilisation de ceux-ci
WO2011044134A1 (fr) 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Dérivés d'épiminocycloalkyl(b)indole utilisés en tant que modulateurs du récepteur de la sérotonine de sous-type 6 (5-ht6) et leurs utilisations
WO2011132051A2 (fr) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
RU2417081C1 (ru) * 2010-05-07 2011-04-27 Ольга Филипповна Сибирева Способ лечения больных хроническим гломерулонефритом в сочетании с хроническим описторхозом
JP6174997B2 (ja) * 2010-06-24 2017-08-02 レオ ファーマ アクティーゼルスカブ ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物
WO2012088124A2 (fr) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Antagonistes de la mch-1 à base de tétrahydro-azacarboline, leurs procédés de fabrication et leurs utilisations
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2012098495A1 (fr) 2011-01-19 2012-07-26 Glenmark Pharmaceuticals Sa Composition pharmaceutique qui comprend le revamilast et un agoniste de bêta-2
WO2012110946A1 (fr) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant l'inhibiteur d'enzyme pde4 révamilast et un agent de modification pathologique, de préférence, le méthotrexate
CA2829045A1 (fr) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Composes et methodes pour le traitement de l'hypertension
WO2012168907A1 (fr) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant du révamilast et du montélukast ou du zafirlukast
WO2013084182A1 (fr) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Composition pharmaceutique comprenant un inhibiteur de l'enzyme pde4 et un agent analgésique
EP2968323A4 (fr) 2013-03-13 2016-12-14 Flatley Discovery Lab Composés de pyridazinone et procédés pour le traitement de fibrose kystique
KR102345381B1 (ko) 2013-06-25 2021-12-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
MX393057B (es) 2014-10-24 2025-03-24 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas.
TWI676618B (zh) 2014-10-24 2019-11-11 美商必治妥美雅史谷比公司 三環化合物
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
JP6472428B2 (ja) * 2015-12-09 2019-02-20 財團法人食品工業發展研究所 キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用
CN112979667B (zh) * 2019-12-02 2022-04-22 首都医科大学 二氧六环修饰的四氢咔啉-3-甲酰-The,其合成,活性和应用
CN112898376B (zh) * 2019-12-02 2022-06-24 首都医科大学 二氧六环修饰的四氢咔啉-3-甲酰-The-HGK,其制备,抗肿瘤活性和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128290A1 (en) * 1995-05-19 2002-09-12 Etsuo Ohshima Derivatives of benzofuran or benzodioxole
WO2004037805A1 (fr) * 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Nouveaux composes tricycliques utiles pour traiter les troubles inflammatoires et allergiques, procede de preparation de ces composes et compositions pharmaceutiques les contenant
WO2004069831A1 (fr) * 2003-02-10 2004-08-19 Glenmark Pharmaceuticals Ltd. Composes tricycliques utiles dans le traitement de troubles inflammatoires et allergiques, et procede de preparation de ces composes
WO2004089940A1 (fr) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041861A (en) 1962-03-14 1966-09-07 Organon Labor Ltd Pyrrolidone derivatives and pharmaceutical preparations containing them
US3759948A (en) * 1969-06-25 1973-09-18 Merck & Co Inc Non-steroid anti-inflammatory compounds
NL7008628A (fr) 1969-06-25 1970-12-29
US3846553A (en) * 1969-12-03 1974-11-05 Merck & Co Inc 3-substituted-2-pyridones in the treatment of pain, fever or inflammation
NL7016899A (fr) 1969-12-03 1971-06-07
US4222944A (en) * 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
JPS62158253A (ja) 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
JPH0812430B2 (ja) 1986-07-07 1996-02-07 キヤノン株式会社 電子写真感光体
ES2032831T5 (es) * 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPS63250378A (ja) * 1987-04-07 1988-10-18 Mitsubishi Kasei Corp インド−ル誘導体
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
WO1993019747A1 (fr) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Composes destines a traiter les maladies allergiques et inflammatoires
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
MX9306311A (es) 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
WO1995009837A1 (fr) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Composes cyano
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
MX9700696A (es) 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
DE69622166T2 (de) * 1995-04-14 2003-04-03 Smithkline Beecham Corp., Philadelphia Dosierinhalator für albuterol
DE19616573C2 (de) * 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
NZ333063A (en) 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
JP3530004B2 (ja) * 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
PL204619B1 (pl) 1998-03-19 2010-01-29 Vertex Pharma Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej
AU3979199A (en) 1998-05-12 1999-11-29 American Home Products Corporation 11-aryl-benzo{b}naphtho{2,3-d}furans and 11-aryl-benzo{b}naphtho{2,3-d}thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6110962A (en) * 1998-05-12 2000-08-29 American Home Products Corporation 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
AU2001239550A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
US20020128920A1 (en) * 2001-03-06 2002-09-12 Dilip Chopra System and method for providing lowest costs purchasing
WO2002072567A2 (fr) 2001-03-13 2002-09-19 Glenmark Pharmaceuticals Limited Nouveaux composes heterocycliques utiles dans le traitement des troubles allergiques inflammatoires; procede de leur preparation et compositions pharmaceutiques les contenant
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128290A1 (en) * 1995-05-19 2002-09-12 Etsuo Ohshima Derivatives of benzofuran or benzodioxole
WO2004037805A1 (fr) * 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Nouveaux composes tricycliques utiles pour traiter les troubles inflammatoires et allergiques, procede de preparation de ces composes et compositions pharmaceutiques les contenant
WO2004069831A1 (fr) * 2003-02-10 2004-08-19 Glenmark Pharmaceuticals Ltd. Composes tricycliques utiles dans le traitement de troubles inflammatoires et allergiques, et procede de preparation de ces composes
WO2004089940A1 (fr) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
NZ555809A (en) 2010-07-30
CA2591438C (fr) 2014-04-29
TWI359814B (en) 2012-03-11
IL183827A0 (en) 2007-09-20
EP1831227B1 (fr) 2013-06-19
KR101317119B1 (ko) 2013-10-11
BRPI0517211A (pt) 2008-09-30
AU2005315319B2 (en) 2011-07-07
EP1831227A2 (fr) 2007-09-12
MA29231B1 (fr) 2008-02-01
IL183827A (en) 2013-02-28
WO2006064355A3 (fr) 2006-08-03
PL1831227T3 (pl) 2013-10-31
AU2005315319A1 (en) 2006-06-22
US8129401B2 (en) 2012-03-06
JP5122974B2 (ja) 2013-01-16
HK1111147A1 (en) 2008-08-01
WO2006064355A2 (fr) 2006-06-22
KR20070100254A (ko) 2007-10-10
TW200634015A (en) 2006-10-01
EA014956B1 (ru) 2011-04-29
CA2591438A1 (fr) 2006-06-22
AP2007004031A0 (en) 2007-06-30
US20110190303A1 (en) 2011-08-04
AR066386A1 (es) 2009-08-19
MY143483A (en) 2011-05-31
BRPI0517211B1 (pt) 2020-08-11
MX2007007345A (es) 2007-09-07
EA200701268A1 (ru) 2007-12-28
BRPI0517211B8 (pt) 2021-05-25
JP2008524201A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
AP2007004031A0 (en) Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1893216A4 (fr) Methodes et preparations pour le traitement de troubles oculaires
IL191772A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL191637A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
PL382308A1 (pl) Związki heterocykliczne i sposoby stosowania
SI1756084T1 (sl) Substituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi s tem
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
PL1644021T3 (pl) Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
EP1874286A4 (fr) Methodes et compositions pour le traitement de troubles anxieux
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
IL178899A0 (en) [3.2.0] heterocyclic compounds and methods of using the same
IL184363A0 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
SI1831227T1 (sl) Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
EP1750698A4 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
EP1812009A4 (fr) Antagonistes des steroides gaba et leur utilisation dans le traitement des troubles du snc
ZA200609778B (en) [3.2.0.] Heterocyclic compounds and methods of using the same
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ZA200805859B (en) Methods and compositions for the treatment of gastriontestinal disorders